La acción de la metformina en diabéticos hospitalizados para el COVID-19
Article Sidebar
Main Article Content
Abstract
Objective: To study the relationship between the decrease in severity and mortality of diabetic patients, users of metformin, with severe COVID-19 in the hospital environment Methods: This is a bibliographical research of scientific relevance of the integrative, observational, transversal, comparative, of a quantitative character. For the selection of articles, a search of the digital bibliography that addresses the topic of the study was carried out in the National Library of Medicine (PubMed) database. Results: It was shown that metformin is effective in improving the clinical picture in hospitalized diabetic patients diagnosed with COVID-19. In 50 selected studies, 23 demonstrated that metformin has different actions, which are anti-inflammatory, immunomodulatory and preventing the entry of SARS-CoV-2 to the target cell, through the blockade of the ACE2 receptor, resulting in a positive response in the reduction of severity and mortality of these patients. Final considerations: Several studies show a beneficial relationship of the use of metformin in diabetic patients and diagnosed with COVID-19, with a significant reduction in the severity of the viral disease, especially in the clinical picture of the patients, where in most cases, there was no evolution to ARDS and no increase in mortality rates.
Article Details
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
References
2. AL-KURAISHY HM, et al. COVID-19 and risk of acute ischemic stroke and acute lung injury in patients with type II diabetes mellitus: the anti-inflammatory role of metformin. Frontiers in Medicine, 2021; 8(2021): 1-10.
3. AZEVEDO MCA, et al. Relação fisiopatológica entre Covid-19 e diabetes mellitus tipo 2: uma revisão narrativa. Revista Eletrônica Acervo Saúde, 2022; 15(4): e10154.
4. BRASIL. 2014. In: Ministério da Saúde. 57,4 milhões de brasileiros têm pelo menos uma doença crônica. Disponível em: https://www.unasus.gov.br/noticia/574-milhoes-de-brasileiros-tem-pelo-menos-uma-doenca-cronica. Acessado em: 31 de maio de 2022.
5. BRASIL. 2020. Ministério da Saúde (MS). Saúde de A a Z. 2020, 2020. Disponível em: https://bvsms.saude.gov.br/diabetes/. Acessado em: 24 de outubro de 2022.
6. CASTRO RMF, et al. Diabetes mellitus e suas complicações-uma revisão sistemática e informativa. Brazilian Journal of Health Review, 2021; 4(1): 3349-3391.
7. CHENG X, et al. Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: a multicentral retrospective study. Life Sciences, 2021; 275(2021): 1-10.
8. CROUSE AB, et al. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. Frontiers in Endocrinology, 2021; 11(600439): 1-8.
9. GHANY R, et al. Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2021; 15(2): 513-518.
10. IBRAHIM S, et al. Metformin and covid-19: focused review of mechanisms and current literature suggesting benefit. Frontiers in Endocrinology, 2021; 12(587801): 1-11.
11. INTERNATIONAL DIABETES FEDERATION. 2021. In: Diabetes facts & figures. Disponível em: https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html. Acessado em: 31 de maio de 2022.
12. KOW CS e HASAN SS. Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: a meta-analysis. Journal of Medical Virology, 2021; 93(2): 695-697.
13. LALLY MA, et al. Metformin is associated with decreased 30-day mortality among nursing home residents infected with SARS-CoV2. Journal of the American Medical Directors Association, 2021; 22(1): 193-198.
14. LIMA-MARTÍNEZ MM, et al. COVID-19 y diabetes mellitus: una relación bidireccional. Clinica e Investigacion en Arteriosclerosis, 2021; 33(3): 151-157.
15. LI J, et al. Metformin Use in Diabetes Prior to Hospitalization: Effects on Mortality in Covid-19, 2020; 26(10):1166-1172.
16. LUKITO AA, et al. The effect of metformin consumption on mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020; 14(6): 2177-2183.
17. LUO P, et al. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. The American journal of tropical medicine and hygiene, 2020; 103(1): 69-72.
18. NAPOLEÃO RNMA, et al. COVID-19: Compreendendo a “tempestade de citocinas”. Research, Society and Development, 2021; 10(5): 1-12.
19. OH TK, SONG I. Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study. Acta diabetologica, 2021; 58(6): 771-778.
20. POLY TN, et al. Metformin use is associated with decreased mortality in COVID-19 patients with diabetes: evidence from retrospective studies and biological mechanism. Journal of clinical medicine, 2021; 10(16): 1-13.
21. SCHEEN AJ. Metformin and COVID-19: from cellular mechanisms to reduced mortality. Diabetes & Metabolismo, 2020; 46(6): 423-426.
22. SHARMA S, et al. Metformin in COVID-19: a possible role beyond diabetes. Diabetes Research and Clinical Practice, 2020; 164(2020): 1-3.
23. SINGH AK, SINGH R. Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19? Diabetes Research and Clinical Practice, 2020; 165(2020): 1-4.
24. SOUZA AKA, et al. Fármacos para o tratamento do diabetes mellitus tipo 2: interferência no peso corporal e mecanismos envolvidos. Rev Ciênc. Med, 2021; 30(2021): 1-11.
25. TAMURA RE, et al. Outcome and death risk of diabetes patients with Covid-19 receiving pre-hospital and in-hospital metformin therapies. Diabetology & Metabolic Syndrome, 2021; 13(1): 1-13.
26. VARGHESE E, et al. Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing. PLoS Pathogens, 2021; 17(6): 1-20.
27. WIERNSPERGER N, et al. Protection by metformin against severe Covid-19: An in-depth mechanistic analysis. Diabetes & Metabolismo, 2022; 48(4): 1-12.
28. WONG CKH, et al. Metformin Use in Relation to Clinical Outcomes and Hyperinflammatory Syndrome Among COVID-19 Patients With Type 2 Diabetes: A Propensity Score Analysis of a Territory-Wide Cohort. Frontiers in Endocrinology, 2022 13(810914): 1-10.
29. WORLD HEALTH ORGANIZATION. 2022. WHO Coronavirus (COVID-19) Dashboard. Disponível em: https://covid19.who.int/. Acessado em: 31 de maio de 2022.
30. YANG W, et al. The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus. Diabetes Research and Clinical Practice, 2021; 178(2021): 1-8.
31. ZANGIABADIAN M, et al. The efficacy and potential mechanisms of metformin in the treatment of COVID-19 in the diabetics: a systematic review. Frontiers in Endocrinology, 2021; 12(645194): 1-9.